{"filings":[{"id":2024255,"accession_number":"0001193125-26-330541","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-08-03T20:05:21+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q2 revenue $10.9M (+18% YoY); revises 2026 guidance to $48-52M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $10.9M (+18% YoY); Biologics & Drug Delivery revenue fell 15% to $4.0M.","Neurosurgery navigation revenue surged 62% to $5.6M on IRRA flow and software.","Operating expenses rose 51% to $17.0M; cash at $29.4M, down from $45.9M at year-end.","2026 revenue guidance revised to $48-52M; company prioritizing clinical capacity and new tech.","Multiple biopharma partners received positive FDA feedback; expects 10-15 trials enrolling in 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582757,"accession_number":"0001193125-26-234571","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-05-21T20:30:16+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro shareholders approve 1M share increase in 2013 incentive plan; board committees reappointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 7th Amended 2013 Incentive Compensation Plan, increasing share pool by 1,000,000 shares to 7,806,250 total.","All seven director nominees elected with >96% votes for each: Burnett, Fallon, Fletcher, Johnson, Klein, Liau, Richards.","Ratification of Cherry Bekaert LLP as auditor: 19.3M for, 20K against; advisory executive compensation approved 8.8M for, 442K against.","Board committees reappointed: Audit (Fallon chair), Compensation (Johnson chair), Governance (Fletcher chair); Fletcher confirmed as Chairman.","Non-employee director annual award cap set at 60,000 shares per year under the amended plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68009,"accession_number":"0001193125-26-221596","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-05-13T20:05:34+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.","Neurosurgery navigation revenue surged 80% to $5.9M, driven by IRRA flow and 3.0 software adoption.","Biologics & drug delivery revenue stable at $4.8M; over 60 active biopharma partners enrolled.","Cash and equivalents $35.6M at Mar 31, 2026; expects cash burn to reduce in H2 2026 from cost synergies.","FDA cleared Velocity Alpha drill used in first clinical procedure; Health Canada MDL license obtained."],"consensus_eps_estimate":-0.2652,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":12128000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102339,"accession_number":"0001193125-26-110780","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.","Full-year 2025 revenue $37.0M, 11th consecutive year of growth; 14% organic YoY increase.","2026 revenue guidance $52-56M, reflecting expected double-digit growth across all four product segments.","Completed IRRAS acquisition in Nov 2025, adding neurocritical care line and $20M additional financing from Oberland Capital.","Cash and equivalents $45.9M at Dec 31, 2025, up from $20.1M a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102336,"accession_number":"0001193125-26-039470","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K/A","filed_at":"2026-02-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"ClearPoint Neuro files financials for acquired IRRAS; IRRAS cash from ops -$11.4M in 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["IRRAS 2024 operating cash outflow $11.4M; accumulated deficit $105.3M.","Gross accounts receivable $1.67M with $22.5K credit loss allowance.","Convertible notes of $6.33M at 5% interest; fair value adjustment recorded $219.6K expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102338,"accession_number":"0001193125-26-009867","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ClearPoint Neuro Q4 2025 prelim revenue $10.4M (+20% YoY); FY2026 guidance $54-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary unaudited revenue ~$10.4M, 20% comparable sales growth over Q4 2024, excluding recent IRRA flow acquisition.","Full year 2025 preliminary revenue ~$37M.","FY2026 revenue guided at $54-60M, driven by organic growth and IRRA flow product integration.","Q4 segment growth: functional neurosurgery disposables +23%, biologics/drug delivery +26%.","Preliminary results subject to revision; audited results expected later in Q1 2026."],"consensus_eps_estimate":-0.204,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":36971000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102337,"accession_number":"0001193125-26-001581","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"ClearPoint Neuro enters consent for Swedish subsidiary reorganization under note purchase agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Consent dated Dec 29, 2025 with TPC Investments III LP (Oberland affiliate) under the May 12, 2025 Note Purchase Agreement.","Company to undertake internal reorganization of IRRAS AB (Swedish sub) and transfer IRRAS USA equity by Jan 15, 2026.","Actions aim to qualify IRRAS AB as an \"Immaterial Foreign Subsidiary\" under the agreement.","Consent does not modify any material economic terms of the Note Purchase Agreement or the Third Sale of $20M notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118615,"accession_number":"0001193125-25-290003","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro completes acquisition of IRRAS for $5M cash + 1.325M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Nov 20, 2025; IRRAS shareholders received $5M cash and 1.325M CLPT shares.","Earnout consideration: 25% of net sales of certain IRRAS products above thresholds over three one-year periods.","IRRAS brings IRRA flow fluid-exchange system for intracranial bleeding, 50+ active customers, and commercial team.","ClearPoint Neuro expects expanded presence in neurocritical care and enhanced commercial scale from the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118614,"accession_number":"0001193125-25-270019","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.","FY2025 revenue guidance narrowed to $36M-$38M; combined 2026 with IRRAS expected $54M-$60M.","Signed agreement to acquire IRRAS Holdings; no purchase price disclosed.","New CAL preclinical facility operational; FDA 510(k) clearance for 1.5T PRISM Laser Therapy.","Active biopharma partners >60; plan to activate 35-40 specialized centers for cell/gene therapy."],"consensus_eps_estimate":-0.204,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":26561000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118613,"accession_number":"0001193125-25-269992","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro to acquire IRRAS for $5M cash + 1.325M shares; combined 2026 rev $54-60M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: $5M cash plus 1.325M ClearPoint shares; earnout of 25% of net IRRA flow sales above thresholds.","IRRAS's IRRA flow catheter addresses ~400K US procedures/yr, targeting a $0.5B global intracranial bleeding market.","IRRAS has >50 active customers and 83% growth in first 9 months of 2025 to ~$9M revenue run-rate.","Combined entity expected to have 40+ additional commercial professionals; 2026 revenue guidance $54M-$60M.","Transaction approved by both boards; closing conditions include IRRAS stockholder approval and Nasdaq Stockholm delisting by Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135101,"accession_number":"0001285550-25-000010","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q2 revenue record $9.2M (+17% YoY); secures up to $105M note financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $9.2M, up 17% YoY; neurosurgery segment revenue up 33% to $3.4M.","Operating expenses $11.2M (+16% YoY); gross margin 60% vs 63% on higher inventory reserves.","Entered $105M note financing with Oberland Capital; $30M funded at closing plus $3.5M stock purchase.","Cash and equivalents $41.5M at June 30, compared to $20.1M at year-end 2024.","Full-year 2025 revenue outlook reaffirmed at $36.0M-$41.0M."],"consensus_eps_estimate":-0.204,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":17700000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152073,"accession_number":"0001683168-25-004550","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro signs 132-month lease for ~30,171 sq ft in San Diego life science building","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with BRE-BMR SCD LLC for office, R&D, and lab space at $5.95/sq ft initial monthly base rent.","Phased occupancy: Phase 1 basement by June 13, 2025; Phase 2 basement by Dec 19, 2025; first floor by July 1, 2026.","Lease term 132 months from last occupancy date with one five-year extension option; base rent escalates 3% annually.","Tenant must provide a $179,517.45 letter of credit as security; free rent periods structured per phase.","Company expanding existing Solana Beach HQ into larger San Diego facility for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152072,"accession_number":"0000950170-25-076992","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro stockholders approve all six proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Joseph M. Burnett received 9,980,965 votes for.","Cherry Bekaert LLP ratified as auditor for FY 2025 with 18,622,225 votes for.","Say-on-pay passed advisory vote; frequency set to one year (9,698,448 votes).","Stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan.","Sixth Amended and Restated 2013 Incentive Compensation Plan approved (8,440,784 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152071,"accession_number":"0000950170-25-074397","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ClearPoint Neuro amends director compensation plan with updated cash retainers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board chair annual retainer increased to $75,000; other members to $45,000 (effective July 1, 2025).","Committee chair retainers: Audit $20,000, Compensation $15,000, Governance $12,000.","Committee member retainers: Audit $10,000, Compensation $7,500, Governance $7,500.","New director one-time RSU grant valued at $150,000; annual RSU grant also $150,000.","Plan last amended May 22, 2023; Board approved latest revision on May 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152070,"accession_number":"0000950170-25-070346","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.","Neurosurgery navigation therapy revenue up 70% to $3.3M; biologics & drug delivery revenue up 9% to $4.7M.","Gross margin 60% (vs 59%); opEx up 29% to $11.3M on higher R&D and headcount.","Cash $12.4M at Mar 31 (down from $20.1M Dec 2024); credit facility secured with Oberland Capital.","FY 2025 revenue guidance reaffirmed at $36M-$41M; FDA clearance for ClearPoint 3.0 software."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":8485000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152069,"accession_number":"0000950170-25-069175","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.","Issues 275,808 shares at $12.69 in registered direct offering for $3.5M gross proceeds.","Notes bear interest at Term SOFR + 3.95% (min 8.25%, cap 9.50%); first six quarters 50% PIK interest.","Proceeds for general corporate purposes; no financial covenants; secured by substantially all assets including IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170894,"accession_number":"0000950170-25-027716","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports record FY2024 revenue $31.4M, 31% growth; guides FY2025 $36-41M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 revenue $31.4M (+31% YoY); Q4 revenue $7.8M (+14% YoY).","Gross margin improved to 61% from 57%; operating expenses rose 8% to $38.9M.","Repaid $10M convertible note; cash $20.1M; operational cash burn down 35% to $9.0M.","2025 revenue guidance $36-41M, implying 15-31% growth.","Biologics/drug delivery revenue up 76% to $18.6M; added 25 new centers in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":31390000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187862,"accession_number":"0001285550-24-000120","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).","Biologics & drug delivery revenue $4.4M (+27%); capital equipment revenue $0.8M (+133%).","Gross margin 60% vs 57% YoY; operating expenses $10M (up from $8.2M) on higher personnel and development costs.","Cash $21.6M; fully repaid $10M convertible note leaving no debt; operational cash burn cut 33% to $1.2M.","Activated 5 new centers in Q3 (19 YTD, ~3x historic rate); FY 2024 revenue outlook held at $30-33M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":23619000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187861,"accession_number":"0001104659-24-115372","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro enters $50M ATM equity offering with Stifel","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with Stifel allows sale of up to $50M in common stock from time to time.","Agent commission of 3.0% of gross sales proceeds; shares sold via Nasdaq Capital Market.","Prospectus supplement filed Nov 7, 2024; registration statement effective since Nov 20, 2023.","Company not obligated to sell any shares; may suspend or terminate offering at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204386,"accession_number":"0001285550-24-000107","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro repays $10M convertible note early, eliminates all debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Aug 23, 2024, fully repaid $10M convertible note held by PTC Therapeutics (orig. maturity Jan 2025).","Note was issued in Jan 2020; early repayment removes all debt from ClearPoint's balance sheet.","CEO says repayment avoids additional dilution and reflects confidence in the business.","PTC continues to support ClearPoint for Upstaza BLA submission to FDA for AADC deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204385,"accession_number":"0001285550-24-000097","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.","Gross margin improved to 63% from 53% a year ago; operating cash burn reduced 47% to $2.7M.","Raised FY2024 revenue guidance to $30-33M from prior; cash position $32.8M after public offering.","Activated 6 new global centers in Q2 (14 YTD); SmartFrame OR and Prism Laser Therapy launched.","Seven pharma partners received expedited FDA review; SmartFlow Cannula approved in Taiwan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":15497000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221145,"accession_number":"0001285550-24-000061","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro stockholders re-elect eight directors, approve incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with over 11.6M votes for each; broker non-votes 6.8M.","Ratification of Cherry Bekaert as auditor: 18.9M for, 68.6K against, 21K abstain.","Advisory say-on-pay approved: 11.1M for, 629.5K against, 431.8K abstain; broker non-votes 6.8M.","Stockholders approved Fifth Amended and Restated 2013 Incentive Compensation Plan: 11.0M for, 699.5K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221144,"accession_number":"0001285550-24-000049","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.","Capital equipment sales surged 255% to $1.4M; SmartFrame OR received 510(k) clearance and first clinical cases performed.","Activated 8 new hospital sites in Q1, a company record, bringing total active sites to over 80.","Operational cash burn reduced 32% to $3.8M; cash and equivalents totaled $35.4M after $16.2M public offering.","Reaffirmed FY2024 revenue outlook of $28M-$32M; first-ever neuro gene therapy BLA submitted by partner PTC Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":7639000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240728,"accession_number":"0001285550-24-000030","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.","Biologics & drug delivery revenue $13.6M in 2023, +49% YoY; gross margin 57% (down from 66%).","Cash & equivalents $23.1M at Dec 31; Q4 cash burn reduced to $1.2M.","Reaffirmed 2024 revenue guidance $28M-$32M; early 2024 milestones include 6 new hospitals, FDA clearance, ~$15M equity offering.","Operating expenses $36.1M in 2023 (up from $29.9M), driven by higher headcount and share-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240727,"accession_number":"0001104659-24-029960","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro prices $15M public offering of 2.3M shares at $6.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,307,694 shares of common stock at $6.50 per share; underwriters have 30-day option for 346,154 additional shares.","Net proceeds expected to be approximately $14.0 million, or $16.2 million if over-allotment option fully exercised.","Proceeds to be used for general corporate purposes, including R&D, potential acquisitions, investments, or debt repayment.","Offering expected to close on or about March 4, 2024; Lake Street Capital Markets is lead underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240726,"accession_number":"0001285550-24-000016","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports Q4 2023 preliminary revenue $6.8M (+32% YoY); guides FY2024 revenue $28-32M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q4 revenue $6.8M, up 32% YoY; biologics/drug delivery revenue $4.1M (+76% YoY).","Full year 2023 record revenue ~$24M (+17% YoY); biologics/drug delivery $13.6M (+49% YoY).","Cash burn ~$1.2M in Q4; cash and equivalents $23.1M at Dec 31, 2023.","FY2024 revenue guidance $28-32M (17-33% growth); expects multiple product launches including SmartFrame OR and PRISM laser.","Company plans to expand to 100 ClearPoint sites by 2025 and demonstrate operating leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":23955000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258224,"accession_number":"0001285550-23-000114","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q3 revenue $5.8M (+12% YoY); biologics & drug delivery up 55% to $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.8M, +12% YoY; biologics & drug delivery $3.5M (+55%) driven by preclinical services.","Gross margin 57% vs 71% prior year due to lower-margin preclinical services and facility transition.","Operational cash burn $1.8M, lowest since 2020; cash $24.3M at Sept 30.","FY 2023 revenue guidance narrowed to $23-25M, representing 11-18% growth.","Entered new strategic biologics agreements; submitted three stereotactic products and updated software to FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":17145000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275540,"accession_number":"0001285550-23-000096","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q2 revenue record $6.0M (+14% YoY); biologics growth 40%; reaffirms FY guide $25-27M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $6.0M, up 14% YoY; biologics & drug delivery revenue $3.4M (+40%).","Gross margin fell to 53% from 63% due to lower-margin preclinical services and facility transition costs.","Operating expenses rose to $10.3M from $7.5M on higher headcount, stock comp, and product development.","Cash & equivalents $26.5M at June 30, down from $37.5M at Dec 2022; operating cash burn $10.8M.","Reaffirmed FY2023 revenue guidance $25-27M; CEO outlines five key milestones for H2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":11383000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275539,"accession_number":"0001285550-23-000091","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro amends debt agreement to appoint PTC as collateral agent and transition to SOFR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["PTC Therapeutics appointed successor collateral agent under the Securities Purchase Agreement, replacing Petrichor.","Interest rate benchmark changed from LIBOR to Adjusted Term SOFR (2% floor + Applicable Margin) effective July 1, 2023.","Petrichor resigns as collateral agent; all liens and security interests assigned to PTC.","Amendment includes SOFR Conforming Changes and fallback to prime rate if Term SOFR is not determinable.","No change to principal amount of senior secured convertible notes; rate structure updated only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293039,"accession_number":"0001285550-23-000050","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro shareholders approve reduction of authorized shares from 200M to 90M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock reduced from 200M to 90M shares; 98.7% of votes cast in favor.","All eight director nominees elected: Burnett, Fletcher, Fallon, Girin, Johnson, Klein, Liau, Richards.","Cherry Bekaert LLP ratified as independent auditor for FY2023; advisory executive compensation approved.","Broker non-votes of 4,856,372 occurred on director elections and executive compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293038,"accession_number":"0001285550-23-000048","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ClearPoint Neuro amends director compensation plan effective May 22, 2023","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Board approved revisions to non-employee director compensation plan; prior version dated May 21, 2022.","Annual retainers: chair $75K, other directors $40K; committee chairs and members receive additional cash retainers.","New directors receive RSU grant valued at $135K vesting in one year; annual RSU grant also $135K for continuing directors.","Directors may elect to receive retainers in common stock in lieu of cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293037,"accession_number":"0001285550-23-000045","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q1 revenue $5.4M (+8% YoY); biologics/drug delivery +24%; reaffirms FY23 guidance $25-27M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.4M (+8% YoY); biologics and drug delivery revenue $2.7M (+24% YoY) drove growth.","Gross margin fell to 59% from 64% due to higher biologics services costs and overhead.","Operating expenses $8.9M vs $7.1M, driven by headcount and stock-based compensation increases.","Cash and short-term investments $31.7M, down from $37.5M; operating cash used $5.7M in quarter.","Reaffirmed full-year 2023 revenue guidance of $25-27M, implying 22-35% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":5433000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313698,"accession_number":"0001285550-23-000022","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"ClearPoint Neuro amends CEO, CFO, COO employment agreements with enhanced severance and equity vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendments extend severance benefits to CEO Burnett, CFO D'Alessandro, and COO Sabra upon company non-renewal of term.","Pre-amendment outstanding time-based options and restricted stock fully vest on qualifying termination (without cause, good reason, or expiration).","Post-amendment awards: only shares scheduled to vest within 12 months of termination accelerate; exercise period reduced to 1 year.","All three executives receive unlimited paid time off under company's Section 16 officer policy.","Definitions of Termination Upon Expiration, Termination Without Cause, and Voluntary Termination revised for clarity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313697,"accession_number":"0001285550-23-000019","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ClearPoint Neuro reports Q4 2022 revenue $5.2M (+21% YoY); full-year revenue $20.6M (+26% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $5.2M, up 21% YoY; full-year revenue $20.6M, up 26% YoY (record).","Biologics & drug delivery revenue $9.1M for 2022, up 34% YoY; over 50 partners.","Gross margin 66% for 2022 vs 68% in 2021; Q4 gross margin 64% vs 77%.","Cash & short-term investments $37.5M at Dec 31, 2022, down from $54.1M.","Reiterates 2023 revenue guidance $25-27M, expecting >20% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":20551000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313696,"accession_number":"0001285550-23-000010","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q4 revenue $5.2M (+21%); FY2022 revenue $20.6M (+26%) missing guidance; FY2023 guide $25-27M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2022 revenue $5.2M (+21% YoY); biologics/drug delivery $2.3M (+37%); functional neurosurgery $2.3M (+7%).","Full year 2022 revenue $20.6M (+26% YoY), below guidance of $21-22M; cash burn $3.0M in Q4; cash $37.5M at year-end.","FY2023 revenue guidance $25-27M (22-31% growth); backlog at highest level; CEO cites Q4 timing issues.","Key upcoming milestones: PTC BLA submission for Upstaza, PRISM laser system commercial launch, 10 new centers, 8 FDA submissions.","Added multiple new biologics/drug delivery partners, total >50; 11 new centers installed in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":20551000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332163,"accession_number":"0001285550-22-000082","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ClearPoint Neuro adopts Fourth Amended and Restated Bylaws with universal proxy, enhanced disclosure rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended bylaws effective Dec. 14, 2022, to comply with SEC universal proxy rules and recent Delaware law changes.","Enhanced procedural mechanics and disclosure requirements for stockholder director nominations and proposals.","Advance notice deadline for stockholder proposals and nominations at annual meetings has been changed.","Updates include conforming edits and ministerial changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332162,"accession_number":"0001285550-22-000076","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q3 revenue $5.1M (+13% YoY); reaffirms FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $5.1M, up 13% YoY; gross margin improved to 72% from 66%.","Cash and short-term investments $40.5M at Sept 30, 2022; reaffirms FY2022 revenue $21-22M.","Partner PTC's Upstaza gene therapy approved in EU; SmartFlow Neuro Cannula included in label.","Added ~50 biologics/drug delivery partners; installed record 10 new systems YTD.","FDA cleared ClearPoint Maestro Brain Model, Prism Neuro Laser Therapy, and navigation software v2.1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":15377000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332161,"accession_number":"0001285550-22-000071","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro signs 10-year lease for 19,462 sq ft Carlsbad facility","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lease commences June 1, 2023; ends May 31, 2033; base rent $36,977.80/month.","Annual rent escalates 3.5%; two extension options (36 or 60 months) at fair market value.","Tenant responsible for insurance, operating, and tax costs; facility is office and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349630,"accession_number":"0001285550-22-000054","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro appoints Mazin Sabra as COO; details employment terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mazin Sabra named COO, effective October 10, 2022, reporting to CEO Joe Burnett.","Sabra brings experience from Philips (VP Supplier Quality Engineering) and Stryker.","Base salary $340,000; target annual bonus 45% of base; signing bonus $110,000.","Granted 46,000 restricted shares vesting over 3 years.","Employment term of 3 years with automatic renewal; severance and change-of-control provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349629,"accession_number":"0001285550-22-000041","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q2 revenue record $5.2M (+52% YoY); reaffirms 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Quarterly revenue $5.2M (record), up 52% YoY; biologics/drug delivery revenue $2.4M +73%.","Partner PTC Therapeutics received EU marketing authorization for Upstaza; uses ClearPoint SmartFlow Neuro Cannula.","Reaffirmed FY2022 revenue guidance of $21-22M.","Cash and short-term investments $45.1M at June 30, 2022.","Added >45 partners; installed 8 systems YTD (4 in Q2)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":10231000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366638,"accession_number":"0001171520-22-000364","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ClearPoint Neuro nullifies authorized share decrease after proxy statement error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At May 24, 2022 Annual Meeting, stockholders approved decreasing authorized shares from 200M to 80M.","Beneficial owner questioned proxy statement inaccuracy on broker discretionary voting for the share decrease proposal.","Company filed Certificate of Correction on June 3, 2022 to nullify the previously filed Certificate of Amendment.","Company will seek stockholder approval again at a future meeting to achieve modest Delaware franchise tax savings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366637,"accession_number":"0001171520-22-000351","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro stockholders approve authorized share reduction from 200M to 80M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common shares reduced from 200M to 80M via Certificate of Amendment.","Eight directors elected, including Joseph Burnett, R. John Fletcher, and Matthew Klein.","Cherry Bekaert LLP ratified as independent auditor for FY 2022; 15.8M for, 19.6K against.","Fourth Amended and Restated 2013 Incentive Compensation Plan approved (8.7M for).","Advisory vote on executive compensation approved with 8.6M for, 887K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366636,"accession_number":"0001171520-22-000319","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ClearPoint Neuro amends director compensation plan; sets retainers and equity grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board chair annual retainer set at $75,000; other members receive $40,000.","Audit committee chair retainer $20,000; members $10,000; compensation and governance chairs $15,000 and $12,000 respectively.","New directors receive restricted stock award valued at $90,000 plus options for 2/3 of RSU shares.","Annual equity grants: each non-employee director gets $90,000 in RSUs plus options (2/3 of RSU count).","Options vest on first anniversary or day before next annual meeting; exercise price at fair market value on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366635,"accession_number":"0001171520-22-000313","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ClearPoint Neuro receives Nasdaq non-compliance notice, cures by reconstituting committees","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ClearPoint Neuro on May 19, 2022 of non-compliance with audit and compensation committee independence rules due to Matthew Klein, M.D. not being independent.","Board reconstituted committees on May 13, 2022: Audit now has Pascal Girin, Lynnette Fallon, R. John Fletcher; Compensation has B. Kristine Johnson and Timothy Richards.","Nasdaq confirmed the company now complies with Listing Rule 5605 following committee changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366634,"accession_number":"0001171520-22-000305","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q1 revenue $5.0M, up 25% YoY; raises FY2022 guidance to $21-22M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $5.0M, a 25% increase vs Q1 2021.","Biologics and drug delivery revenue $2.2M (+30% YoY); functional neurosurgery revenue $2.2M (+17%).","Operating expenses $7.1M, up from $4.8M in Q1 2021, driven by headcount and R&D.","Cash position $49.7M at March 31, 2022 vs $54.1M at year-end 2021.","Raised FY2022 revenue guidance to $21.0-22.0M, representing 30-35% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":5031000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386060,"accession_number":"0001171520-22-000183","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ClearPoint Neuro reports Q4 revenue $4.3M (+15%) and record 2021 revenue $16.3M (+27%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $4.3M (+15% YoY); full-year revenue $16.3M (+27% YoY), seventh consecutive year of growth.","Biologics & drug delivery revenue $6.8M in 2021 (+31% YoY); supported 929 cases despite COVID.","Cash and equivalents $54.1M at year-end, up from $20.1M, aided by Feb 2021 public offering raising ~$46.8M net.","Operating expenses increased to $24.7M (2021) from $15.3M (2020) due to headcount and R&D investments.","2022 revenue guidance reaffirmed at $20-22M; progress on pillars including FDA clearance for Array and BCI collab."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":16299000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386059,"accession_number":"0001171520-22-000133","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports Q4 rev $4.3M (+15% YoY); FY2021 rev record $16.3M (+27% YoY); 2022 guidance $20-22M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $4.3M, up 15% YoY; functional neurosurgery products $2.1M (+37%), biologics/drug delivery $1.7M (+10%).","Full-year 2021 record revenue $16.3M (+27% YoY) and record case volume 929 (+36% YoY), within initial guidance of $16-17.5M.","Cash and equivalents $54.1M at year-end; management states no need for additional capital in 2022.","2022 revenue guidance $20-22M, representing growth of 23-35% YoY; COVID variant risk cited as key factor.","Earnings call scheduled for March 1, 2022 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":16299000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386058,"accession_number":"0001171520-22-000126","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ClearPoint Neuro COO Peter Piferi resigns, will serve as interim head of regulatory under consulting agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter G. Piferi voluntarily resigned as COO effective Feb 18, 2022; not due to any disagreement with management.","He entered a consulting agreement effective Feb 21, 2022, for up to 2 months (with possible month-to-month extension up to 2 years).","Will receive $5,000 cash separation, continued vesting of stock options and restricted stock, and $10,000/month consulting fee.","Consulting services include transitioning job functions and serving as Interim Head of Regulatory for ClearPoint Neuro."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403969,"accession_number":"0001171520-21-000553","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2021-12-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ClearPoint Neuro adopts amended bylaws with exclusive forum provision","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Third Amended and Restated Bylaws effective December 16, 2021.","Changes conform to Delaware law, include technical edits and exclusive forum provision.","No financial or operational impact disclosed; routine governance update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403968,"accession_number":"0001171520-21-000516","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q3 revenue $4.6M record, up 30% YoY; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $4.6M (+30% YoY); biologics/drug delivery $2.1M (+39%).","Functional neurosurgery revenue $2.2M (+17%); capital equipment $0.4M (+78%).","Gross margin 68% vs 74% due to inventory reserves and overhead.","R&D spend $2.6M (+130%) driven by headcount and platform expansion.","Cash $57.7M; guidance: FY revenue $16-17.5M, case volume 900-1000."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":12017000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-09T23:59:59+00:00|403968"}